FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.
Oncogene – Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer
Click on the article title to read more.
The FDA has given the novel agent NVL-655 a breakthrough therapy designation for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell…
Immune cells convert an immunosuppressive lipid into an anticancer immunity enhancer.
To combat the rising costs of cancer care, clinicians are partnering with managed service organizations to handle the business aspects of practice.
Saliby et al. show that a machine learning approach can accurately classify clear cell renal cell carcinoma (RCC) into distinct molecular subtypes using transcriptomic data. When…
Kids who need specialized cancer care outside their home state face bureaucratic hurdles that cause dangerous delays. But there’s hope. The Accelerating Kids…
Editorial Fellowship Program | Blood | American Society of Hematology .myButton { background-color:#b7000f; border-radius:3px; border:none; display:inline-block; cursor:pointer; color:#fff!important; font-family:Arial; font-size:18px; padding:12px 24px; text-decoration:none; } .myButton:hover…